Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko(Revolution Medicines (United States)), Miroslav Sekulic(NewYork–Presbyterian Hospital), Clint A. Stalnecker(University of North Carolina at Chapel Hill), Melissa M. Ronan(Broad Institute), Tanner C. Dalton(Columbia University Irving Medical Center), Marie Ménard(University of California, San Francisco), Kristina Drizyte‐Miller(University of North Carolina at Chapel Hill), James M. Cleary(Brigham and Women's Hospital), Connor J. Hennessey(Broad Institute), William P. Vostrejs(University of Pennsylvania), Yu Chi Yang(Revolution Medicines (United States)), Gulam A. Manji(NewYork–Presbyterian Hospital), Stephen A. Sastra(Columbia University Irving Medical Center), Natalie K. Barker(University of North Carolina at Chapel Hill), Julien Dilly(Massachusetts Institute of Technology), Sha Tian(Macau University of Science and Technology), Yingyun Wang(Revolution Medicines (United States)), Kenneth Y. Tsai(Moffitt Cancer Center), Nicholas D. Socci, Brian M. Wolpin(Harvard University), Priya S. Hibshman(University of North Carolina at Chapel Hill), Jennifer A. Roth(Broad Institute), Laura E. Herring(University of North Carolina at Chapel Hill), Samantha B. Kemp(University of Michigan), Margo Orlen(UPMC Hillman Cancer Center), Basil Bakir(University of Pennsylvania), Matthew G. Rees(Broad Institute), Stephanie Chang, John A. Chabot(Columbia University Irving Medical Center), Lingyan Jiang(Hainan University), Michael D. Kluger(Columbia University Irving Medical Center), Álvaro Curiel‐García(Columbia University Irving Medical Center), Amanda R. Decker-Farrell(Columbia University Irving Medical Center), Rina Sor(University of Pennsylvania), Haley Courtney(Revolution Medicines (United States)), Amber M. Amparo(University of North Carolina at Chapel Hill), Marie C. Hasselluhn(Columbia University Irving Medical Center), Carmine F. Palermo(Columbia University Irving Medical Center), Lorenzo Tomassoni(Columbia University Irving Medical Center), Cynthia Clendenin(University of Pennsylvania), Yevgeniy Gindin(Revolution Medicines (United States)), Ruiping Zhao(Hebei North University), Jens Brodbeck(Revolution Medicines (United States)), Bianca J. Lee(Revolution Medicines (United States)), Ciara Helland(Revolution Medicines (United States)), Karl Muonio(Revolution Medicines (United States)), Junning Wang(Dana-Farber Cancer Institute), Jingjing Jiang(Revolution Medicines (United States)), A. Cole Edwards(University of North Carolina at Chapel Hill)
Cited by 175
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724